Galapagos NV has expanded its global strategic alliance in metabolic diseases with an affiliate of Merck to incorporate the development of new therapies for atherosclerosis. Galapagos will be responsible for the discovery and preclinical development of new small molecule candidate drugs based on novel Galapagos targets. The alliance will make use of Galapagos’ proprietary target discovery platform for identification of novel targets in atherosclerosis, as well as in obesity and diabetes...